Targets › IDO1
8 programs from 6 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.
Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway. Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses. (UniProt, P14902)
Open in Phaseline: the race on IDO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IO Biotech | IO102-IO103 Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I | IDO1, CD274 | Phase 3 | Metastatic Melanoma | Sep 2027 |
| Memorial Sloan Kettering Cancer Center | Epacadostat Indoleamine 2,3-dioxygenase inhibitor | IDO1 | Phase 2 | Sarcoma | Jan 2027 |
| IO Biotech | IO102 IDO1 peptide | IDO1 | Phase 2 | Melanoma | Jan 2027 |
| University Hospital, Basel, Switzerland | indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor IDO-1 inhibitor | IDO1 | Phase 2 | EBV Infections | Feb 2027 |
| Memorial Sloan Kettering Cancer Center | Linrodostat (BMS-986205) Indoleamine 2,3-dioxygenase inhibitor | IDO1 | Phase 2 | Endometrial Adenocarcinoma | Sep 2027 |
| University of California, Davis | IO102-IO103 Peptide Vaccine PD-L1/IDO peptide vaccine activating T-cells against tumor and immune suppressive cells | CD274, IDO1 | Phase 1 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Dec 2026 |
| Northwestern University | Linrodostat (BMS-986205) Indoleamine 2,3-dioxygenase inhibitor | IDO1 | Phase 1 | Glioblastoma | Feb 2027 |
| Washington University School of Medicine | Epacadostat (INCB024360) Indoleamine 2,3-dioxygenase inhibitor | IDO1 | Phase 1 | Rectal Cancer | Jul 2027 |
Sarcoma (1) EBV Infections (1) Endometrial Adenocarcinoma (1) Glioblastoma (1) High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma (1) Metastatic Melanoma (1) Melanoma (1) Rectal Cancer (1)
mixed (6), protein or peptide (1), small molecule (1)
Memorial Sloan Kettering Cancer Center (2) IO Biotech (2) University Hospital, Basel, Switzerland (1) Northwestern University (1) University of California, Davis (1) Washington University School of Medicine (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.